For instance, in a clinical trial (NCT02410733), 119 melanoma patients received the BNT111 mRNA vaccine containing four TAAs: New York esophageal squamous cell carcinoma 1 (NY-ESO-1), melanoma antigen family A3 (MAGE-A3), transmembrane phosphatase with tensin homolog (TPTET), and tyrosinase. This evidence concerns the gene MAGEA3 and melanoma.